According to available information, there is limited data on the potential risks of Lipitor (atorvastatin) in breast milk and its effects on babies. The U.S. National Library of Medicine's LactMed database states that "after a single 80 mg oral dose of atorvastatin to nursing mothers, atorvastatin was not detected in breast milk and only low levels of its metabolites were found." However, it is important to note that "the effects on the nursing infant are unknown" [1].

The manufacturer of Lipitor, Pfizer, states in the drug's prescribing information that "it is not known whether atorvastatin is excreted in human milk" and recommends that "because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother" [2].

DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical industry news, does not have specific information on the risks of Lipitor in breast milk [3].

In summary, while there is limited data on the potential risks of Lipitor in breast milk, it is recommended that women consult with their healthcare provider before taking the drug while nursing, due to the potential for serious adverse reactions in infants.

Sources:

1. LactMed. Atorvastatin. <https://www.ncbi.nlm.nih.gov/books/NBK501893/>
2. Pfizer. Lipitor (atorvastatin calcium) tablets, for oral use. Full Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/20267s5333lbl.pdf>
3. DrugPatentWatch.com. Lipitor. <https://www.drugpatentwatch.com/drugs/lipitor>